Maxwell Biosciences Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
22
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$20M
- Investors
-
31
Maxwell Biosciences General Information
Description
Operator of a drug platform company intended to create biomimetic therapeutics and synthetic compounds that mimic and improve upon biomolecules. The company's platform effectively destroys viruses, bacteria, fungi, and some cancers while avoiding healthy cells in human tissues and animal studies, where compounds imitate key immune system components, enabling healthcare professionals to treat formerly untreatable conditions.
Contact Information
Website
www.maxwellbiosciences.comCorporate Office
- 3809 Juniper Trace
- Suite 101
- Austin, TX 78738
- United States
Corporate Office
- 3809 Juniper Trace
- Suite 101
- Austin, TX 78738
- United States
Maxwell Biosciences Timeline
Maxwell Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 05-Aug-2025 | $20M | Completed | Pre-Clinical Trials | ||
| 7. Secondary Transaction - Private | Completed | Pre-Clinical Trials | ||||
| 6. Later Stage VC | Cancelled | Pre-Clinical Trials | ||||
| 5. Seed Round | 01-Oct-2023 | Completed | Pre-Clinical Trials | |||
| 4. Accelerator/Incubator | 14-Oct-2022 | Completed | Pre-Clinical Trials | |||
| 3. Grant | 01-Sep-2021 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 30-Jun-2021 | $4.7M | $4.7M | Completed | Pre-Clinical Trials | |
| 1. Grant | $35M | Completed | Startup |
Maxwell Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed-1 | ||||||||
| Seed-5 | ||||||||
| Seed-7 | ||||||||
| Seed-6 | ||||||||
| Seed-4 | ||||||||
| Seed-3 | 1,200,000 | $0.000010 | $0.1 | $0.1 | 1x | $0.1 | 1.47% | |
| Seed-2 | 8,700,000 | $0.000010 | $0.07 | $0.07 | 1x | $0.07 | 10.69% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Maxwell Biosciences Comparisons
Industry
Financing
Details
Maxwell Biosciences Competitors (5)
One of Maxwell Biosciences’s 5 competitors is Abivax, a Formerly PE-Backed company based in Paris, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Abivax | Formerly PE-Backed | Paris, France | ||||
| NiKang Therapeutics | Venture Capital-Backed | Wilmington, DE | ||||
| Molecular Partners | Formerly VC-backed | Zurich, Switzerland | ||||
| Moderna France | Formerly PE-Backed | Lucon, France | ||||
| Glaxosmithkline Biologicals | Corporation | Saint-Amand-Les-Eaux, France |
Maxwell Biosciences Patents
Maxwell Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026136558-A1 | Peptoids for inhibition of nasal pathogen infections, and compositions and methods for administration thereof | Pending | 20-Dec-2024 | ||
| US-20250282821-A1 | Lipopolysaccharide-binding peptoids, and compositions and methods of use thereof | Pending | 08-Mar-2024 | ||
| WO-2025189073-A1 | Lipopolysaccharide-binding peptoids, and compositions and methods of use thereof | Pending | 08-Mar-2024 | ||
| WO-2025189073-A8 | Lipopolysaccharide-binding peptoids, and compositions and methods of use thereof | Pending | 08-Mar-2024 | ||
| US-20250268809-A1 | Broad-spectrum peptoids for oral and dental hygiene, and compositions and methods of use thereof | Pending | 23-Feb-2024 | A61K38/08 |
Maxwell Biosciences Signals
Maxwell Biosciences Investors (31)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Transform Investments | Venture Capital | Minority | ||
| 3Rodeo | Venture Capital | Minority | ||
| Accelerator Venture Partners | Venture Capital | Minority | ||
| Angel Star Ventures | Angel Group | Minority | ||
| Angel (individual) | Minority |
Maxwell Biosciences FAQs
-
When was Maxwell Biosciences founded?
Maxwell Biosciences was founded in 2016.
-
Where is Maxwell Biosciences headquartered?
Maxwell Biosciences is headquartered in Austin, TX.
-
What is the size of Maxwell Biosciences?
Maxwell Biosciences has 22 total employees.
-
What industry is Maxwell Biosciences in?
Maxwell Biosciences’s primary industry is Drug Discovery.
-
Is Maxwell Biosciences a private or public company?
Maxwell Biosciences is a Private company.
-
What is Maxwell Biosciences’s current revenue?
The current revenue for Maxwell Biosciences is .
-
How much funding has Maxwell Biosciences raised over time?
Maxwell Biosciences has raised $35.6M.
-
Who are Maxwell Biosciences’s investors?
Transform Investments, 3Rodeo, Accelerator Venture Partners, Angel Star Ventures, and are 5 of 31 investors who have invested in Maxwell Biosciences.
-
Who are Maxwell Biosciences’s competitors?
Abivax, NiKang Therapeutics, Molecular Partners, Moderna France, and Glaxosmithkline Biologicals are competitors of Maxwell Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process